Sunscreen and frontal fibrosing alopecia: A review - 11/02/20
Abstract |
Frontal fibrosing alopecia (FFA) is a cicatricial alopecia of unknown etiology. The incidence of FFA appears to be increasing with time, leading to suspicion of a possible environmental trigger. Observational studies have reported a positive correlation between facial sunscreen use and FFA. This finding raises the question of whether sunscreen use plays a role in disease development. In this article, we review the available literature on the association of sunscreen with FFA. There is insufficient evidence to establish a direct causal relationship between sunscreen and FFA. Further studies are required to better characterize the role of sunscreen and the environment in the pathogenesis of this unique disease.
Le texte complet de cet article est disponible en PDF.Key words : alopecia, frontal fibrosing alopecia, hair, hair loss, inflammatory hair disorder, lichen planopilaris, primary lymphocytic cicatricial alopecia, scarring, sunscreen, titanium dioxide, ultraviolet filter
Abbreviations used : FFA, TiO2, UV
Plan
Funding sources: None. |
|
Conflicts of interest: Drs Robinson and Wang have no conflicts of interest to disclose. Dr McMichael has served as an investigator for Aclaris Therapeutics, Cassiopea, Concert Pharmaceuticals, Incyte, Procter and Gamble Pharmaceuticals, and Samumed and has served as a consultant for Aclaris Therapeutics, Allergan, Bioniz Therapeutics, Cassiopea, Covance, eResearch Technology, Inc, Galderma, Incyte, Johnson & Johnson, KeraNetics, Merck & Co, Inc, Pfizer, Procter & Gamble Pharmaceuticals, and Samumed. She has received grants from Allergan, Concert Pharmaceuticals, and Procter & Gamble and receives royalties from Informa Healthcare and UpToDate. Dr Lim has served as an investigator for Estée Lauder, Ferndale Pharma Group, Unigen, Incyte, and Beiersdorf; he has also served as a consultant for Pierre Fabre, ISDIN, and Ferndale Pharma Group and has participated as a speaker in an educational session for Pierre Fabre and Eli Lilly. |
|
IRB approval status: Not applicable. |
|
Reprints not available from the authors. |
Vol 82 - N° 3
P. 723-728 - mars 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?